ArticleThe European respiratory journal2024
Mortality surrogates in combined pulmonary fibrosis and emphysema.
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- A syndromic framework for progressive pulmonary fibrosis.Respiratory research · 2026Review
- Transforming lung transplantation with artificial intelligence: a narrative review from organ allocation to post-transplant management.Journal of thoracic disease · 2026Review
- Does combined pulmonary fibrosis and emphysema syndrome affect response to antifibrotic therapy and survival? A single-center retrospective cohort study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Radiomics and Artificial Intelligence in Pulmonary Fibrosis.Journal of imaging informatics in medicine · 2025Review
- Comparing survival outcomes of anti-fibrotic therapy for idiopathic pulmonary fibrosis with and without emphysema: a multi-center real-world study from Taiwan.BMC pulmonary medicine · 2025Article
- Review of the Diagnosis and Management of Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).Journal of clinical medicine · 2025Review
- Review
- Pulmonary hypertension associated with lung diseases.The European respiratory journal · 2024Review
- Imaging in the diagnosis and management of fibrosing interstitial lung diseases.Breathe (Sheffield, England) · 2024Review
Corrections and comments
- Commented on by
Authors and funding
43 authors at 18 institutions in 6 countries.
Funding
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) with coexistent emphysema, termed combined pulmonary fibrosis and emphysema (CPFE) may associate with reduced forced vital capacity (FVC) declines compared to non-CPFE IPF patients. We examined associations between mortality and functional measures of disease progression in two IPF cohorts.
methodsVisual emphysema presence (>0% emphysema) scored on computed tomography identified CPFE patients (CPFE/non-CPFE: derivation cohort n=317/n=183, replication cohort n=358/n=152), who were subgrouped using 10% or 15% visual emphysema thresholds, and an unsupervised machine-learning model considering emphysema and interstitial lung disease extents. Baseline characteristics, 1-year relative FVC and diffusing capacity of the lung for carbon monoxide (
resultsIn both IPF cohorts, CPFE patients with ≥10% emphysema had a greater smoking history and lower baseline
conclusionWhen assessing disease progression in IPF,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.